Accessibility Menu
 
Avalo Therapeutics logo

Avalo Therapeutics

(NASDAQ) AVTX

Current Price$14.70
Market Cap$328.61M
Since IPO (2015)-100%
5 Year-100%
1 Year+211%
1 Month-6%

Avalo Therapeutics Financials at a Glance

Market Cap

$328.61M

Revenue (TTM)

$59.00K

Net Income (TTM)

$78.26M

EPS (TTM)

$-6.10

P/E Ratio

-2.37

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$14.70

Volume

593,150.307

Open

$14.80

Previous Close

$14.42

Daily Range

$14.40 - $15.27

52-Week Range

$3.39 - $20.72

AVTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avalo Therapeutics

Industry

Biotechnology

Employees

33

CEO

Garry Arthur Neil, MD

Headquarters

Rockville, MD 20850, US

AVTX Financials

Key Financial Metrics (TTM)

Gross Margin

73%

Operating Margin

-1236%

Net Income Margin

-1326%

Return on Equity

-72%

Return on Capital

-70%

Return on Assets

-67%

Earnings Yield

-42.19%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$328.61M

Shares Outstanding

22.79M

Volume

593.15K

Short Interest

0.00%

Avg. Volume

651.54K

Financials (TTM)

Gross Profit

$285.00K

Operating Income

$72.92M

EBITDA

$72.92M

Operating Cash Flow

$51.46M

Capital Expenditure

$0.00

Free Cash Flow

$51.46M

Cash & ST Invst.

$98.34M

Total Debt

$2.43M

Avalo Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$59.00K

-69.3%

Gross Profit

$43.00K

-59.0%

Gross Margin

72.88%

N/A

Market Cap

$328.61M

N/A

Market Cap/Employee

$14.29M

N/A

Employees

23

N/A

Net Income

$13.72M

+61.2%

EBITDA

$19.73M

-49.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$95.91M

-28.4%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$2.04M

N/A

Short Term Debt

$392.00K

-31.0%

Return on Assets

-67.20%

N/A

Return on Invested Capital

-70.45%

N/A

Free Cash Flow

$14.25M

+5.3%

Operating Cash Flow

$14.25M

+5.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENTAEnanta Pharmaceuticals, Inc.
$14.09+0.21%
IVAInventiva S.A.
$5.73+1.78%
OBIOOrchestra BioMed Holdings, Inc.
$4.58+2.35%
PRLDPrelude Therapeutics Incorporated
$4.36-1.69%

Trending Stocks

Symbol / CompanyPricePrice Chg
EFOIEnergy Focus
$7.12+2.41%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.88+0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$58.45+0.04%
IBITiShares Bitcoin Trust
$43.80+0.03%

Questions About AVTX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.